PCMC inspects over 5.4 lakh homes to tackle Dengue and Malaria spread
In a large-scale campaign spanning across all eight zones, the civic body has inspected over 5.43 lakh homes and nearly 29 lakh water containers in search of mosquito breeding sites. The drive also covered more than 1,200 scrap yards and over 1,600 construction sites.
So far, breeding-friendly conditions were found in the surroundings of 9,680 houses and in over 10,548 water containers. Notices have been issued at 3,431 locations, and penalties have been imposed on 624 households and commercial establishments resulting in the collection of Rs 22.24 lakh in fines, health officials said.
Under the guidance of Municipal Commissioner Shekhar Singh, Additional Commissioner Vijaykumar Khorate, and Deputy Commissioner Sachin Pawar, the PCMC health department has adopted a multipronged strategy. This includes not only identifying and eliminating mosquito breeding grounds but also increasing public awareness and taking punitive action wherever necessary, the civic administration said.
The campaign involves regular insecticide spraying, household visits by health workers, and the distribution of information pamphlets. In addition, the corporation is running awareness programs in schools and conducting cleanliness drives in public spaces and high-risk areas, officials said.
The civic body has appealed to residents to actively support the campaign by keeping their surroundings clean, especially during the rainy season. Citizens are advised to clean water storage containers every week, keep them covered at all times, and observe one 'dry day' each week to prevent mosquito breeding.
Municipal Commissioner Shekhar Singh said, 'PCMC is adopting a comprehensive approach to combat dengue and malaria—through larval source elimination, rigorous inspections, and strong awareness campaigns. We urge citizens to actively participate by keeping their surroundings clean and supporting this city-wide effort.'
Deputy Commissioner Sachin Pawar added, 'We are reviewing the ward-wise implementation of all anti-mosquito measures. Public support is crucial—every household must observe one dry day each week to prevent mosquito breeding.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
2 minutes ago
- Economic Times
Potential US tariff a significant 'unknown' for business, says Dr Reddy's Lab CEO
Dr. Reddy's Laboratories is closely monitoring a potential US tariff on the pharma sector, viewing it as both a risk and opportunity. The company plans a significant expansion with the generic version of semaglutide across 87 countries by 2026, alongside developing 26 GLP-1 products over the next decade. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads A potential US tariff on the pharma sector is a significant 'unknown' and will be one of the key developments for Dr Reddy's Laboratories to watch over the next few quarters, its chief executive officer, Erez Israeli , told ET.'Don't know whether to call it a risk, but it is an unknown that could develop into a risk, and that is the tariff. We will know better as time will come about what it means and what we can do,' Israeli said over an earning call on Wednesday. 'It's not necessarily bad, it can also create an opportunity. It very much depends on what will be our relative situation to Chinese players or others.'The Hyderabad-based drug maker, which announced its first-quarter earnings, is betting big on generic version of Novo Nordisk 's weight loss molecule semaglutide – that it plans to launch in 87 countries in 2026 - as a future growth driver.'Our levers for the future consist of double-digit growth of the main business and then on top of it the success of semaglutide, which is very important to us, business development and our ability to optimise our resources,' Israeli said in response to ET's query.'We are planning to launch semaglutide in 87 countries as the patent in the relevant country will allow us… We have some countries where there is no active patent as we speak, and in those we can launch. In the other countries, we need to wait for the patent expiration - for example Brazil or India - in which the patent goes on till March 2026. We are absolutely ready to launch on day 1 (post patent expiry) in each one of these markets,' he company which is among the frontrunners for GLP-1 drugs is looking at launching 26 other products in the space over the next decade.'We have 26 products (all peptides) in the GLP1 pipeline and will be launched over the next decade, according to the patent situation,' said Wednesday, the company reported consolidated revenue for the first quarter at Rs 8,545 crore, an 11% increase from a year ago, mainly on account of contributions from its acquired consumer healthcare portfolio in nicotine replacement therapy (NRT) and sustained performance in branded markets. Net profit for the quarter stood at Rs 1,418 crore, up 2% said an ongoing litigation over semaglutide with innovator company Novo Nordisk in India is not likely to hamper its planned product company's global generics revenue in Q1FY26 stood at Rs 7,562 crore, a growth of 10% revenue from North America–one of its key markets–declined 11% y-o-y to Rs 3,412 crore due to increased price erosion in select products, including lenalidomide. Its Europe revenue stood at Rs 1,274 crore, up 142% on account of NRT portfolio company's India and emerging markets business grew 11% and 17% company's EBITDA margin for the first quarter stood at 26.7%.
Time of India
20 minutes ago
- Time of India
Potential US tariff a significant 'unknown' for business, says Dr Reddy's Lab CEO
A potential US tariff on the pharma sector is a significant 'unknown' and will be one of the key developments for Dr Reddy's Laboratories to watch over the next few quarters, its chief executive officer, Erez Israeli , told ET. 'Don't know whether to call it a risk, but it is an unknown that could develop into a risk, and that is the tariff. We will know better as time will come about what it means and what we can do,' Israeli said over an earning call on Wednesday. 'It's not necessarily bad, it can also create an opportunity. It very much depends on what will be our relative situation to Chinese players or others.' Explore courses from Top Institutes in Please select course: Select a Course Category Technology Leadership Project Management Healthcare Management Data Analytics Data Science others Cybersecurity Artificial Intelligence Design Thinking Degree Product Management Public Policy Data Science MCA Finance MBA Others healthcare Operations Management PGDM CXO Digital Marketing Skills you'll gain: Duration: 12 Weeks MIT xPRO CERT-MIT XPRO Building AI Prod India Starts on undefined Get Details The Hyderabad-based drug maker, which announced its first-quarter earnings, is betting big on generic version of Novo Nordisk 's weight loss molecule semaglutide – that it plans to launch in 87 countries in 2026 - as a future growth driver. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like No annual fees for life UnionBank Credit Card Apply Now Undo 'Our levers for the future consist of double-digit growth of the main business and then on top of it the success of semaglutide, which is very important to us, business development and our ability to optimise our resources,' Israeli said in response to ET's query. 'We are planning to launch semaglutide in 87 countries as the patent in the relevant country will allow us… We have some countries where there is no active patent as we speak, and in those we can launch. In the other countries, we need to wait for the patent expiration - for example Brazil or India - in which the patent goes on till March 2026. We are absolutely ready to launch on day 1 (post patent expiry) in each one of these markets,' he said. Live Events The company which is among the frontrunners for GLP-1 drugs is looking at launching 26 other products in the space over the next decade. 'We have 26 products (all peptides) in the GLP1 pipeline and will be launched over the next decade, according to the patent situation,' said Israeli. On Wednesday, the company reported consolidated revenue for the first quarter at Rs 8,545 crore, an 11% increase from a year ago, mainly on account of contributions from its acquired consumer healthcare portfolio in nicotine replacement therapy (NRT) and sustained performance in branded markets. Net profit for the quarter stood at Rs 1,418 crore, up 2% y-o-y. Israeli said an ongoing litigation over semaglutide with innovator company Novo Nordisk in India is not likely to hamper its planned product launches. The company's global generics revenue in Q1FY26 stood at Rs 7,562 crore, a growth of 10% year-on-year. However, revenue from North America–one of its key markets–declined 11% y-o-y to Rs 3,412 crore due to increased price erosion in select products, including lenalidomide. Its Europe revenue stood at Rs 1,274 crore, up 142% on account of NRT portfolio acquisition. The company's India and emerging markets business grew 11% and 17% respectively. The company's EBITDA margin for the first quarter stood at 26.7%.
New Indian Express
2 hours ago
- New Indian Express
Karnataka government aids a grieving wife to bring back mortal remains of her husband from Guyana
MADIKERI: The Karnataka government has come to the aid of a bereaved wife who lost her husband to illness in Guyana of South America. The State will pay Rs 3.6 lakh to bring the victim's mortal remains to India. The deceased PB Girish was a resident of Madenadu village in Kodagu. He was working as a staff nurse at a hospital in Guyana of South America. He fell ill and was under medical assistance from July 3. He is said to have succumbed to a heart attack at a hospital in Guyana on July 14. However, the family learnt that it would cost them about Rs 12 lakh to bring the mortal remains of Girish back to India. Following it, Girish's wife Janaki met CM Siddaramaiah and requested help from the state to pay the amount to bring back the mortal remains. The victim's kin had also approached Virajpet MLA AS Ponnanna seeking help. Following these developments, the Under Secretary to the Government of the State Protocol, Foreign Cell Personnel and Administrative Reforms Department, has directed the Commissioner of Karnataka Bhavan in New Delhi to pay Rs 3.6 lakh to bring Girish's mortal remains back to his homeland. The rest of the amount will be borne by the Sheriff General Hospital at Guyana, where Girish served as the staff nurse. The Indian Embassy at Guyana will initiate steps to bring the body back to the country at the earliest.
